Regulatory News:
Neovacs (Paris:ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.
The liquidity account had the following holdings as of December 31, 2013:
- 25,939 shares
- ?164,598.35
For the prior six month period (June 30, 2013), the corresponding figures were:
- 28,223 shares
- ?151,698.16
About Neovacs
Neovacs is a biotechnology company focused on
an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the
company's proprietary technology for inducing a polyclonal immune
response (covered by five patent families that run until at least 2023)
Neovacs is focusing its development efforts on two active
immunotherapies: TNF-Kinoid is being developed for the treatment of
TNF-mediated autoimmune diseases such as rheumatoid arthritis and
Crohn's disease, whereas IFN?-Kinoid is being developed for the
indication of lupus. The goal of the Kinoid approach is to enable
patients to have access to safe treatments with efficacy that is
sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
NEOVACS
Nathalie Trépo, +33 (0)1 53 10 93 00
ntrepo@neovacs.com
or
Press
? ALIZE RP
Caroline Carmagnol, +33 (0)1 70 22 53 86
caroline@alizerp.com
or
Investors
- NewCap
Valentine Brouchot/Pierre Laurent, + 33 (0) 1 44 71 94
93
neovacs@newcap.fr